<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="67674">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02224846</url>
  </required_header>
  <id_info>
    <org_study_id>15382</org_study_id>
    <secondary_id>H6D-GH-B022</secondary_id>
    <nct_id>NCT02224846</nct_id>
  </id_info>
  <brief_title>A Study of Tadalafil (LY450190) in Chinese Men With Erectile Dysfunction</brief_title>
  <official_title>Postmarketing Surveillance Study: A Randomized, Open-Label, 3-Month Interventional Study of Tadalafil Effectiveness (2.5 mg and 5 mg) and Long-Term Safety Administered Once Daily in Chinese Men With Erectile Dysfunction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and effectiveness of the study drug,
      taken once daily, known as tadalafil in Chinese participants with erectile dysfunction (ED).
      The study will last about up to 25 months for each participant.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>October 2014</start_date>
  <completion_date type="Anticipated">May 2017</completion_date>
  <primary_completion_date type="Actual">May 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of Participants Experiencing at Least One Treatment Emergent Adverse Event (Serious or Non-Serious)</measure>
    <time_frame>Baseline through Month 12</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in the International Index of Erectile Function- Erectile Function (IIEF-EF) Domain Questionnaire Score of 2.5 Milligrams (mg) Tadalafil</measure>
    <time_frame>Baseline, Month 1, Month 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in the IIEF-EF Domain Questionnaire Score of 5 mg Tadalafil</measure>
    <time_frame>Baseline, Month 1, Month 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in the IIEF-EF Domain Questionnaire Score of 5 mg Tadalafil Treatments</measure>
    <time_frame>Baseline, Month 6, Month 12, Month 18, Month 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants with &quot;Yes&quot; Responses to Sexual Encounter Profile (SEP) Diary of 2.5 mg Tadalafil</measure>
    <time_frame>Month 1 and Month 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants with &quot;Yes&quot; Responses to SEP Diary of 5 mg Tadalafil</measure>
    <time_frame>Month 1 and Month 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants Achieving Normal Erectile Functioning of 2.5 mg Tadalafil</measure>
    <time_frame>Month 1 and Month 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants Achieving Normal Erectile Functioning of 5 mg Tadalafil</measure>
    <time_frame>Month 1 and Month 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants Achieving Normal Erectile Functioning of 5 mg Tadalafil Treatments</measure>
    <time_frame>Month 6, Month 12, Month 18 and Month 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants with &quot;Yes&quot; Responses to GAQ1 and GAQ2 of 5 mg Tadalafil</measure>
    <time_frame>Month 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants with &quot;Yes&quot; Responses to GAQ1 and GAQ2 of 5 mg Tadalafil Treatments</measure>
    <time_frame>Month 12 and Month 24</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Erectile Dysfunction</condition>
  <arm_group>
    <arm_group_label>2.5 mg/5 mg tadalafil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2.5 mg tadalafil orally once daily for 3 months (Period 1) and then 5 mg tadalafil orally once daily for 21 months (Period 2).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>5 mg tadalafil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5 mg tadalafil orally once daily for 24 months (Period 1 and Period 2).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tadalafil</intervention_name>
    <description>Administered orally</description>
    <arm_group_label>2.5 mg/5 mg tadalafil</arm_group_label>
    <arm_group_label>5 mg tadalafil</arm_group_label>
    <other_name>LY450190</other_name>
    <other_name>Cialis</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Have a history of erectile dysfunction for at least 3 months.

          -  Are sexually active and willing to remain sexually active with the same female
             partner during the study.

          -  Are willing to have 4 or more attempts of sexual intercourse with female partner
             between screening and first treatment start day.

          -  Are willing to stay away from any other medicines that the participants were already
             taking for erectile dysfunction during this study period.

        Exclusion Criteria:

          -  Have erectile dysfunction, which is caused by any other primary sexual disorder.

          -  Have certain problems with kidneys, liver, heart, blood sugar levels, eyes, or
             central nervous system (study doctor will discuss with participants).

          -  Have a penis deformity or penile implant that in the opinion of the participants'
             doctor is significant.

          -  Have human immunodeficiency virus (HIV) infection.

          -  Are using certain kinds of medicines, which are not allowed in this study.

          -  Are allergic to tadalafil.

          -  Are planning to father a baby or are in a relationship with a pregnant partner.

          -  Are participating or discontinued participation in the past 30 days from any another
             clinical trial, which is not compatible with this trial.

          -  Have participated or discontinued from any other tadalafil clinical trial.

          -  Have a history of drug, alcohol, or substance abuse within the past 6 months.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>22 Years</minimum_age>
    <maximum_age>69 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Beijing</city>
        <zip>100020</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Changchun</city>
        <zip>130021</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Changsha</city>
        <zip>410011</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Chengdu</city>
        <zip>610083</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Chongqing</city>
        <zip>400037</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Fuzhou</city>
        <zip>350001</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Guangzhou</city>
        <zip>510180</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Hangzhou</city>
        <zip>310003</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Hefei</city>
        <zip>230022</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Nanjing</city>
        <zip>210008</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Qingdao</city>
        <zip>266071</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Shanghai</city>
        <zip>200092</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Suzhou City</city>
        <zip>215004</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Wenzhou</city>
        <zip>325035</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Wu Han</city>
        <zip>430030</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Wuhan</city>
        <zip>430022</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Yinchuan</city>
        <zip>750004</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2016</verification_date>
  <lastchanged_date>June 3, 2016</lastchanged_date>
  <firstreceived_date>August 20, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Erectile Dysfunction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Tadalafil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
